Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Abstract Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy, regardless of biomarker status. Howeve...

Full description

Bibliographic Details
Main Authors: Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng
Format: Article
Language:English
Published: BMC 2024-05-01
Series:Trials
Subjects:
Homologous recombination–deficient
Interval debulking surgery
Neoadjuvant chemotherapy
Niraparib
Ovarian cancer
Overall response rate
Online Access:https://doi.org/10.1186/s13063-024-08142-5

Internet

https://doi.org/10.1186/s13063-024-08142-5

Similar Items